Harvard Bioscience, Inc. (NASDAQ:HBIO) Sees Large Decrease in Short Interest

Harvard Bioscience, Inc. (NASDAQ:HBIO) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 374,100 shares, a drop of 6.2% from the October 31st total of 398,900 shares. Based on an average daily volume of 136,800 shares, the short-interest ratio is currently 2.7 days.

Institutional Investors Weigh In On Harvard Bioscience

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Harvey Partners LLC boosted its holdings in Harvard Bioscience by 6.2% in the third quarter. Harvey Partners LLC now owns 2,715,000 shares of the medical instruments supplier’s stock valued at $7,303,000 after purchasing an additional 157,500 shares during the period. Assenagon Asset Management S.A. lifted its position in shares of Harvard Bioscience by 193.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 227,701 shares of the medical instruments supplier’s stock worth $649,000 after buying an additional 150,218 shares during the last quarter. Acuitas Investments LLC boosted its holdings in shares of Harvard Bioscience by 24.8% in the 2nd quarter. Acuitas Investments LLC now owns 407,343 shares of the medical instruments supplier’s stock valued at $1,161,000 after buying an additional 80,827 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Harvard Bioscience by 2.4% in the 1st quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock valued at $9,125,000 after buying an additional 49,576 shares during the last quarter. Finally, Gabelli Funds LLC acquired a new stake in Harvard Bioscience during the 2nd quarter worth $128,000. Institutional investors and hedge funds own 80.87% of the company’s stock.

Harvard Bioscience Price Performance

Harvard Bioscience stock traded up $0.03 during mid-day trading on Tuesday, reaching $2.23. 16,454 shares of the company’s stock traded hands, compared to its average volume of 119,661. Harvard Bioscience has a 12-month low of $1.99 and a 12-month high of $5.56. The company has a market cap of $97.27 million, a price-to-earnings ratio of -6.67 and a beta of 1.27. The company has a quick ratio of 0.91, a current ratio of 2.06 and a debt-to-equity ratio of 0.52. The stock has a 50 day moving average of $2.39 and a two-hundred day moving average of $2.77.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.